替罗非班对急性心梗患者急诊PCI中冠脉内血栓的影响

目的:探讨替罗非班对ST段抬高急性心肌梗死患者直接经皮冠状动脉内介入治疗(PCI)中冠状动脉内血栓的影响。方法:79例患者,随机分为试验组(替罗非班 PCI,34例)和对照组(直接PCI,45例)。观察住院期间主要心血管事件(MACE)发生率,冠状动脉内血栓和使用替罗非班的不良反应。结果:与对照组相比,试验组于术前应用替罗非班使PCI术前梗死相关血管(IRA)内血栓存在比例明显降低(P<0.05);试验组出血发生率较对照组有增多趋势(P>0.05)。结论:早期使用血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班,可以明显减少STEMI梗死相关血管内血栓的发生率。

Effect of Tirofiban on Intra-coronary Thrombosis in Patients with STEMI During Emergency PCI

Objective:To explore the effect of tirofiban on intra-coronary thrombosis in patients with the ST-segment elevation myocardial infarction(STEMI) during emergency percutaneous coronary intervention(PCI).Methods:79 patients with STEMI were ran-domly divided into two groups:the experimental group(n=34), treated with tirofiban before PCI;the control group(n=45), treated with PCI only.During hospitalization,the inpatients were observed in the major adverse cardiovascular events(MACE) rate, intra-coronary thrombosis incidence and adverse reaction of tirofiban.Results Compared with the control group,the percentage of thrombosis in the in-farction-related arteries(IRA) obviously decreased(P<0.05).The hemorrhage incidence in the experimental group was higher than that in the control group(P>0.05).Conclusion:In the early stage using tirofiban, the platelet glycoprotein receptor antagonist, can reduce inci-dence of thrombosis in the IRA of patients with STEMI.